1. Central neurotoxicity induced by trastuzumab emtansine (T-DM1): a case report
- Author
-
Marilita M Moschos, Konstantinos A A Douglas, Vivian Paraskevi Douglas, Sergios Tsakatikas, Christos Kosmas, Alexandros D Liatsos, Georgios I Papageorgiou, and David G Symeonidis
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Receptor, ErbB-2 ,Vision Disorders ,Breast Neoplasms ,Ado-Trastuzumab Emtansine ,chemistry.chemical_compound ,Antineoplastic Agents, Immunological ,Blurred vision ,Trastuzumab ,Internal medicine ,Diplopia ,medicine ,Humans ,Pharmacology (medical) ,skin and connective tissue diseases ,Adverse effect ,Pharmacology ,Taxane ,business.industry ,Cancer ,Middle Aged ,medicine.disease ,Discontinuation ,Peripheral neuropathy ,chemistry ,Trastuzumab emtansine ,Female ,medicine.symptom ,business ,medicine.drug - Abstract
Trastuzumab emtansine (T-DM1) is a human epidermal growth factor receptor 2 (Her2) - targeted antibody-drug conjugate that is approved for patients previously treated with trastuzumab and a taxane for Her2-positive advanced breast cancer and those who have progressed within 6 months of completion of adjuvant chemotherapy, as well as for patients with residual invasive Her2-positive disease after the completion of adjuvant chemotherapy. Peripheral neuropathy is a common adverse event; however, ocular events have also been described. With the current report we present the case of a 67-year old woman who developed transient grade 2-3 blurred vision after the first T-DM1 infusion, which was complicated with grade 2 diplopia causing vertigo after the second infusion. After extended investigation, this symptomatology was attributed to central neurotoxicity, and gradually resolved after T-DM1 discontinuation.
- Published
- 2021